FDA OKs Third New PEP Product, J&J’s Renamed Pancreaze

Johnson & Johnson (J&J) has received FDA approval for its delayed-release Pancreaze capsules for the treatment of exocrine pancreatic insufficiency. The drug is a pancreatic enzyme product (PEP), used to improve food digestion in patients whose bodies do not produce enough pancreatic enzymes due to cystic fibrosis and other conditions, the company says. It is the third PEP to be approved by the FDA, the agency says.
Washington Drug Letter